Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + S-1 in High-Risk Postoperative Intrahepatic Cholangiocarcinoma
NCT06664021Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: 1-year Recurrence-Free Survival Rate. Started Nov 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06664021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664021.